Canada markets closed
  • S&P/TSX

    20,138.35
    +88.88 (+0.44%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • DOW

    34,479.60
    +13.36 (+0.04%)
     
  • CAD/USD

    0.8228
    -0.0041 (-0.50%)
     
  • CRUDE OIL

    70.78
    +0.49 (+0.70%)
     
  • BTC-CAD

    43,412.92
    -1,748.84 (-3.87%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • GOLD FUTURES

    1,879.50
    -16.90 (-0.89%)
     
  • RUSSELL 2000

    2,335.81
    +24.40 (+1.06%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • NASDAQ

    14,069.42
    +49.09 (+0.35%)
     
  • VOLATILITY

    15.65
    -0.45 (-2.80%)
     
  • FTSE

    7,134.06
    +45.88 (+0.65%)
     
  • NIKKEI 225

    28,948.73
    -9.83 (-0.03%)
     
  • CAD/EUR

    0.6792
    +0.0003 (+0.04%)
     

Stocks in play: PharmaTher Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

A wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) announced it has entered into an exclusive research collaboration agreement with Revive Therapeutics Ltd. (CSE: RVV, USA: RVVTF) to expand Revive’s development plans with psilocybin to treat cancer and to discover novel uses of undisclosed psychedelic compounds. "We are excited to partner with Revive Therapeutics on our psilocybin cancer program and on panaceAI™ to unlock the potential novel uses of psychedelic compounds in diseases that have sub-optimal or no treatment options,” said Fabio Chianelli, CEO of PharmaTher Inc. The research collaboration with Revive is PharmaTher’s first partnership with panaceAI and it validates PharmaTher’s business model in discovering novel uses of psychedelics and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics. PharmaTher Inc. shares C.PHRM are trading down 2.78 percent at $0.18.

Read: